All In Biotech

Drug Trial Radar · NCT07904195

Specific Immunotherapy With Mannan-Conjugated Allergoids for HDM-Allergic Rhinitis/Rhinoconjunctivitis_MM09-SIT-069.

Prospective, Randomised, Double-blind, Placebo-controlled Multicentre Trial of Efficacy and Safety of D. Pteronyssinus/D. Farinae Mannan-conjugated Allergoids in Patients With Mite-allergic Rhinitis/Rhinoconjunctivitis.

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 250 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

250

Planned (sponsor's estimate)

Start

Apr 15, 2026

Primary completion

Jul 2029

Study completion Jul 2029

Sponsor

Lead sponsor
Inmunotek S.L.Industry
Sponsor type
Industry
Collaborators
Astrum CRO, S.L.; Eurofins
First posted
Oct 29, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 12 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn whether EP-088\_MM09 works to treat house dust mite allergy. It will also assess the treatment's safety. EP-088\_MM09 contains modified house dust mite allergens called mannan-conjugated allergoids. The study plans to include 250 participants aged 12 to 65 years. They will have persistent, moderate to severe nasal allergy symptoms, with or without eye symptoms. Participants may also have mild or moderate allergic asthma, provided it is controlled. The main questions are: * Does the treatment lower allergy symptoms and the need for symptom-relief medicines compared with a placebo? * What medical problems or reactions occur during treatment? Researchers will assess how well the treatment works using a score combining symptoms and medication use. The main assessment will cover four weeks after the treatment course. Participants will be assigned by chance to receive either EP-088\_MM09 or a placebo. They will have an equal chance of receiving either treatment. The placebo looks like EP-088\_MM09 but contains no active ingredients. Neither participants nor study doctors will know which treatment each participant receives. Each participant will be in the study for approximately 14 to 21 months. Participants will: * Attend one or two visits before starting treatment to check whether they can take part. * Attend 12 treatment visits, approximately once a month, to receive injections under the skin. They will receive two injections at the first treatment visit and one at each later visit. * Stay at the clinic for at least 30 minutes after each injection. * Record symptoms and medication use daily during specified periods. * Complete questionnaires about their symptoms and quality of life, and provide blood samples. * Attend a final visit about one month after the last treatment visit. Participants who are also sensitive to pollen may need a second visit before starting treatment. This is needed if their first visit falls during the relevant pollen season or within one month before or after it.

Conditions

  • Allergic Rhinitis
  • Allergic Rhinoconjunctivitis
  • Allergic Asthma

Interventions

  • EP-088_MM09Biological

    The composition of the active IMP (EP-088\_MM09) is as follows: * Dermatophagoides pteronyssinus mannan-conjugated (polymerized) allergoid. * Dermatophagoides farinae mannan-conjugated (polymerized) allergoid. The concentration of the Dermatophagoides mixture is 3,000 mTU/mL. Inmunotek has found it convenient to define 1 mTU (Therapeutic Unit of mannan) as the result of polymerising and conjugating 10 biological units of the corresponding semi-purified native extract with mannan.

  • PlaceboBiological

    The composition of the placebo IMP is as follows: • Identical in composition to the active IMP, but without active ingredients.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rhinitis/Rhinoconjunctivitis Combined Symptom and Medication Score (RCSMS) by means of the Subject's DiaryTime frame: Baseline Visit or Additional Baseline visit (2 weeks), visit 3 (2 weeks), visit 6 (2 weeks), visit 9 (2 weeks) and visit 12 (4 weeks)

Locations

16 sites in 2 countries. Site status is shown where the registry gives one.

  • Unidade Local de Saúde de Braga, EPE

    Braga, Portugal · Not yet recruiting

  • Unidade Local de Saúde da Lezíria

    Santarém, Portugal · Not yet recruiting

  • Unidade Local de Saúde de Cova da Beira

    Covilha, Castelo Branco District, Portugal · Not yet recruiting

  • Unidade Local de Saúde do Algarve, EPE

    Portimão, Faro District, Portugal · Not yet recruiting

  • Hospital do Divino Espirito Santo

    Ponta Delgada, Ilha de São Miguel, Portugal · Not yet recruiting

  • Unidade Local de Saúde Amadora Sintra, EPE

    Amadora, Lisbon District, Portugal · Not yet recruiting

  • Quriónsalud Alicante

    Alicante, Spain · Recruiting

  • HLA CM La Salud

    Cadiz, Spain · Not yet recruiting

  • Hospital Materno Infantil - Hospital Universitario Regional de Málaga

    Málaga, Spain · Not yet recruiting

  • H. Quriónsalud Malaga

    Málaga, Spain · Active not recruiting

  • Hosp. Rafael Méndez de Lorca

    Murcia, Spain · Not yet recruiting

  • Hospital Ribera-Povisa

    Valencia, Spain · Not yet recruiting

  • Hospital U. y Politécnico La Fe

    Valencia, Spain · Recruiting

  • Hospital General U. de Elche

    Elche, Alicante, Spain · Not yet recruiting

  • Clinica Dermatología y Alergia

    Badajoz, Extremadura, Spain · Active not recruiting

  • Complejo Hospitalario Universitario Insular Materno-Infantil

    Las Palmas de Gran Canaria, Gran Canaria, Spain · Active not recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.